UNSPSC 51182103: Conivaptan

This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NJ98Y462X, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but generally known as conivaptan, which bears US NIH Compound Identifier 151171. European Medicines Agency schedules Conivaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32706.

UNSPSC 51182103 Conivaptan, a Commodity code, identifies a vasopressin-receptor antagonist pharmaceutical used to treat hyponatremia in hospitalized patients. State and local governments procure conivaptan primarily through their correctional health systems, state hospitals, and county detention facilities, where the drug treats severe electrolyte imbalances in inmate and patient populations. The code also sees procurement from state Medicaid agencies and county health departments acquiring the drug for qualifying patients in custody or in state-funded treatment settings. Purchasing bodies include state departments of corrections, county sheriff offices operating detention medical services, state psychiatric hospital systems, and county health authorities. Conivaptan procurement is typically handled through state pharmaceutical contracts, group purchasing cooperative vehicles such as those managed through the National Association of State Procurement Officials (NASPO), or direct RFQ to pharmaceutical distributors that serve institutional health systems.

The source does not contain recent state and local contract opportunities posted under this code. The absence of visible activity reflects the drug's narrow therapeutic indication and the fact that conivaptan procurement is often consolidated under broader pharmaceutical supply contracts or state health-system formulary agreements rather than issued as standalone solicitations. Firms pursuing correctional pharmaceutical or institutional health supply contracts should monitor state DOC health services RFPs and county detention health service solicitations, which may bundle conivaptan with other IV infusion therapies and injectable pharmaceuticals without isolating the drug in a separate line item.